Form 4: Praxis Precision Medicines CEO Awarded Stock and Options
SEC Form 4 Filing
Praxis Precision Medicines CEO, Marcio Souza, received 37,500 restricted stock units and options for 75,000 shares on January 10, 2025.
Summary
- Marcio Souza, CEO of Praxis Precision Medicines, was granted 37,500 restricted stock units and options to purchase 75,000 shares of common stock on January 10, 2025.
- The restricted stock units vest in equal annual installments over four years, starting January 10, 2026.
- The stock options vest over four years, with 25% vesting on January 10, 2026, and the remaining 75% vesting monthly over the following three years.
- Souza also indirectly owns 3,000 shares of common stock held by his spouse.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.
Positives
- The grant of restricted stock units and stock options aligns the CEO's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Industry Context
This type of equity compensation is common for executives in publicly traded companies, particularly in the biotech sector, to incentivize performance and align interests with shareholders.
Comparison to Industry Standards
- Equity grants to CEOs are a standard practice in the biotechnology industry.
- The vesting schedules described are typical for such grants, with a mix of time-based and performance-based vesting often used.
- Companies like Biogen, Vertex Pharmaceuticals, and Regeneron also use similar equity compensation packages for their executives.
Stakeholder Impact
- The equity grants may positively impact shareholder value by incentivizing the CEO to improve company performance.
- The grants do not have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Date of the grant of restricted stock units and stock options. |
| 01/10/2026 | First vesting date for 25% of the stock options and the first annual vesting date for the restricted stock units. |
| 01/10/2035 | Expiration date of the stock options. |
| 01/14/2025 | Date the form was signed by the attorney-in-fact. |
Keywords
stock options, restricted stock units, insider trading, executive compensation, Praxis Precision Medicines, equity awards, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.